MEETING OF THE BUSINESS AND FINANCE COMMITTEE:

The Business and Finance Committee was called to order at 8:45AM by Regent Mueller. Roll call was taken and Regents Mueller, Pruitt, Delgado, Grebe, Hall, Harsy and Vasquez were in attendance.

I.2.a. Approval of the Minutes of the June 4, 2015 Meeting of the Business and Finance Committee

Upon the motion of Regent Vasquez and the second of Regent Pruitt, the committee unanimously approved the minutes of the June 4, 2015 meeting of the Business and Finance Committee.

I.2.b. UW-Madison Contractual Agreement – Novartis Pharmaceuticals Corporation

Upon the motion of Regent Delgado and the second of Regent Hall, the committee approved a UW-Madison service agreement and amendment with Novartis Pharmaceuticals Corporation. The agreement involves a clinical study regarding the use of certain substances for the treatment of premenopausal women with advanced breast cancers. Efforts under the agreement are expected to be conducted through September 2018. Novartis is expected to pay the institution $665,469. Research work under the agreement will be conducted in the Department of Medicine, Comprehensive Cancer Center under the direction of Kari Wisinski.

I.2.c. UW-Madison Contractual Agreement – Genentech, Inc.

Upon the motion of Regent Vasquez and the second of Regent Pruitt, the committee approved a UW-Madison agreement with Genentech, Inc. The agreement involves a clinical study to assess the efficacy and safety of certain treatments in patients with idiopathic pulmonary fibrosis. The research study is expected to run through March 2016 and Genentech will pay the institution $692,126 for the work. The research will be conducted in the Department of Pulmonary Medicine under the direction of Keith Meyer, M.D.

I.2.d. UW-Madison Contractual Agreement – Madison Vaccines, Inc.

Upon the motion of Regent Delgado and the second of Regent Hall, the committee approved a UW-Madison agreement with Madison Vaccines, Inc. The agreement involves a Phase I investigator-initiated clinical trial. Efforts under the agreement are expected to run for approximately five years. Madison Vaccines, Inc. is expected to pay the University $1,506,437 under the agreement. The research will be conducted in the Department of Medicine, Comprehensive Cancer Center, under the direction of Christos Kryiokopoulos.

The Committee adjourned at 8:59AM.

Respectfully submitted,

Jennie Bauernhuber
Recording Secretary